Eric W Linsley

Bio

Eric is an experienced operating executive and venture capital investor who prior to joining Pappas Ventures in 2000 served as Chief Financial Officer of TriPath Imaging, Inc. (Nasdaq: TPTH), a medical device company that was acquired in 2006 by Becton Dickinson. Eric played a key role in the three-way merger between AutoCyte, NeoPath and Neuromedical Systems that created TriPath. Prior to the formation of TriPath, he served as Chief Financial Officer and Vice President of Operations at AutoCyte where he led the company in a successful public equity offering in 1997. From 1991 to 1997, Eric worked as an investment professional with Ampersand Ventures, a leading venture capital firm based in Boston. As a partner at Ampersand, he held interim management positions in operating and financial roles for various industrial products and healthcare companies. He previously served as a management consultant with Bain & Co. and McKinsey & Co., and was a certified public accountant with Arthur Andersen LLP. Eric is currently a director of BaroSense and an observer at LipoScience and Liquidia Technologies. Previously, he was a director at BioSyntech, Cequent Pharmaceuticals (acquired by Marina Biotech in 2010), Emerald BioAgriculture, FlowCardia (acquired by C.R. Bard in 2010), Gentis, Signase and Sensys. He was also an observer at Anthera Pharmaceuticals, which went public in early 2010. Eric served on the board of directors of Panacos Pharmaceuticals, and played a key role in its successful reverse merger with a publicly-traded company. He was directly responsible for the investment by Pappas Ventures II in Peninsula Pharmaceuticals, which Johnson & Johnson acquired in 2005 at a substantial premium, and later Cerexa, which was acquired by Forest Laboratories in 2007. Trinity College (BA in Economics). New York University (MS in Accounting). Wharton School at the University of Pennsylvania (MBA).